Cellectar Biosciences Reports Results From Case Study Highlighting Durable Complete Response In Heavily Pretreated Patient With Diffuse Large B-Cell Lymphoma Treated With Iopofosine I 131

Durable Complete Response Achieved with Single Administration of Iopofosine I 131 

Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential Utility Across a Range of B-cell Malignancies

FLORHAM PARK, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today reported results from a case study highlighting a durable complete response in a heavily pretreated patient with diffuse large B-cell lymphoma (DLBCL) treated with iopofosine I 131.

The case study describes a 53-year-old woman with high-grade, double-hit DLBCL who had received four prior lines of therapy. This case demonstrates that a single administration of iopofosine I 131 produced a durable complete response lasting more than eight years in a patient with aggressive, relapsed DLBCL following multiple prior therapies and stem cell transplantation. The Company plans to submit these findings for journal publication or presentation at a medical meeting.